GNG8 encodes G protein subunit gamma 8, a component of heterotrimeric G proteins that functions as a modulator in transmembrane signaling systems. As part of the Gβγ dimer, GNG8 is required for GTPase activity, GDP-GTP exchange, and G protein-effector interactions [UniProt], positioning it centrally in G protein-coupled receptor signaling and cellular signal transduction. Mechanistically, GNG8 participates in G protein-coupled receptor (GPCR) signaling pathways through its assembly into heterotrimeric complexes and its GTPase activity [GO Annotations]. The gene has been identified as involved in WNT/β-catenin signaling 1, a pathway critical for cellular differentiation and proliferation. Disease relevance spans multiple malignancies and metabolic disorders. GNG8 emerged as a hub susceptibility gene in skeletal muscle of Type 2 Diabetes Mellitus patients 2, implicating it in glucose metabolism and insulin resistance. In cancer contexts, GNG8 was identified among immunotherapy-predictive genes in hepatocellular carcinoma 3, included in diagnostic models for neuropathic pain 4, and identified as a key PANoptosis-related gene in breast cancer prognosis 5. GNG8 was also part of an immune-related prognostic signature for cervical cancer 6, and transcriptomic analysis linked GNG8 expression to CAR-T cell migration capacity in glioblastoma models 7. Clinically, GNG8's inclusion in multiple disease prediction models suggests potential utility as a biomarker for prognosis and immunotherapy response assessment across cancer types and metabolic diseases, though functional validation remains necessary.